Skip to content

Feasibility and Efficacy of Portable Non-invasive Negative Pressure Ventilation in Fontan Patients

Feasibility and Efficacy Of Negative Pressure Ventilation in Fontan populatioN: Cardiovascular Flow Assessment by Magnetic Resonance Imaging

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03251742
Acronym
FONTAN-CMR
Enrollment
20
Registered
2017-08-16
Start date
2017-11-17
Completion date
2018-05-01
Last updated
2018-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fontan Physiology

Keywords

Fontan operation, Negative pressure ventilation, MRI

Brief summary

The human heart has 4 chambers: 2 collecting chambers (atria) and 2 pumping chambers (ventricles) to allow blood flow within two distinct circuits: pulmonary and systemic. The pulmonary circuit directs the blood to the lungs to receive oxygen and the systemic circuit delivers oxygen-rich blood throughout the body. In children born with a single ventricle, blood from these two circuits mixes within the heart resulting in lower oxygen levels in the blood delivered to the body (cyanosis). The Fontan procedure is a palliative surgery which bypasses the need for a ventricle to deliver blood to the lungs, as blood from the body flows passively to the lungs by a man-made connection (whereby two large body veins \[cavae\] are sewn to the pulmonary arteries), thereby preventing mixing of blood through restoration of two distinct circuits without mixing of blood. Although the Fontan operation effectively eliminates cyanosis and enables survival into adulthood, increased systemic venous pressure is an unavoidable systemic complication and low cardiac output (CO) is pervasive finding. Despite excellent pediatric surgical results, the risk of late complications and death dramatically increases in the decades following Fontan surgery. A chronically low CO state secondary to decreased forward flow of blood to the lungs can result in end-organ dysfunction and shortened life expectancy. Short of heart transplantation, deemed suitable only for a minority of patients, effective therapies for low CO are largely absent. The investigators aim to investigate a novel, non-invasive, ambulatory therapy which can augment CO. Specifically, external suction is applied intermittently to the chest wall, much like a vacuum, to increase CO, called negative pressure ventilation (NPV) using a Cuirass® ventilator (Hayek Medical). Although used in patients with lung disease, the investigators' proposal is to evaluate this novel, portable, ventilation system would be the first study of its kind in adults with congenital heart disease, specifically those with a Fontan palliation.

Interventions

Negative pressure ventilation in Fontan patients.

Sponsors

Hayek Medical
CollaboratorUNKNOWN
University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

This is a cross-sectional study designed to evaluate the immediate impact of negative pressure ventilation (NPV) in an ambulatory Fontan population using cardiovascular magnetic resonance imaging (CMR) for assessment of cardiovascular flows.

Eligibility

Sex/Gender
ALL
Age
13 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Fontan patients age \> 13 years.

Exclusion criteria

* unable to complete MRI (pacemaker/defibrillator/retained wires, pregnancy, claustrophobia); * evidence of Fontan failure (requiring ongoing medical / device therapy) protein-losing enteropathy, intracardiac thrombus, anatomical obstruction to the Fontan circuit; * patent Fontan fenestration; * oxygen saturation \< 90%; * ongoing arrhythmia; * ejection fraction \< 50% on echocardiography or CMR; * moderate or severe valve insufficiency on echocardiography or CMR; * Obesity (BMI \>35); * severe obstructive sleep apnea (AHI\>20); * chronic obstructive lung disease (FEV1/FVC\<60%); * severe chest wall deformities (scoliosis, kyphosis, kyphoscoliosis); * acute or chronic kidney disease (eGFR\<60) * unable to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Efficacy of the NPV on cardiac output6-8 monthsCardiac output will be measured in L/min/m2 using phase contrast MRI. Flow measurements will be made at baseline and with application of the device.
Efficacy of the NPV on organ perfusion6-8 monthsMulti organ perfusion will be measured in L/min/m2 using phase contrast MRI. Flow measurements will be made at baseline and with application of the device.

Secondary

MeasureTime frameDescription
Tolerability and safety of negative pressure ventilation.6-8 monthsAssessed by participant questionnaire rating tolerance, safety, overall satisfaction with the device.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026